Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca.
Ticagrelor is an antagonist of the P2Y12 receptor.
Medical uses
Ticagrelor is used for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. The drug is combined with acetylsalicylic acid unless the latter is contraindicated. There is no high quality evidence for the use of ticagrelor in non-ST elevation acute coronary syndrome.
The FDA indication for ticagrelor is reduction of the rate of cardiovascular death, myocardial infarction (MI), and stroke in people with acute coronary syndrome or history of myocardial infarction.
AHA/ACC Guidelines (09/2014) state: "It is reasonable to choose ticagrelor over clopidogrel for P2Y12 inhibition treatment in patients with NSTE-ACS treated with early invasive strategy and/or coronary stenting"
Product Description:
| Product Name | Ticagrelor |
| CAS | 274693-27-5 |
| Category | API |
| Quality Standard | EP/USP |
| MSDS | Available |
| COA | Contact with Senwayer for updated version COA. |
| Sample | Available |
| MOQ | 1g,1kg |
| Delivery Date | In 3 days |
| Place Of Origin | China |
| Application | Pharmaceutical raw materials |
| Brand Name | Senwayer |
Specifications:
| Items | Specifications | Results |
| Appearance | White to whitish crystal powder | Conforms |
| Loss on drying | NMT 0.5% | 0.33% |
| Residue on ignition | NMT 0.1% | Conforms |
| Heavy metal | NMT 20ppm | Conforms |
| Assay (HPLC) | NLT 99.5% | 99.77% |
| Related substances | NMT 0.5% | 0.23% |
| Single impurity | NMT 0.1% | 0.07% |
| Conclusion: Complies to the Enterprise standard | ||
Packaging & Shipping:
Available of Ticagrelor:
| Size | Stock |
| 100 g | In-stock |
| 1 kg | In-stock |
| 10 kg | In-stock |
| 25 kg | Inquiry |
Shipping item: CIP by courier to your door(UPS, FedEx, DHL, EMS).
Delivery time: Within 3 days after receive payment.
没有评论:
发表评论